AxoGen (AXGN) Competitors

AxoGen (NASDAQ:AXGN) and NovoCure (NASDAQ:NVCR) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their dividends, community ranking, risk, institutional ownership, profitability, valuation, earnings, media sentiment and analyst recommendations.

Does the media favor AXGN or NVCR?

In the previous week, NovoCure had 15 more articles in the media than AxoGen. MarketBeat recorded 19 mentions for NovoCure and 4 mentions for AxoGen. AxoGen's average media sentiment score of 1.03 beat NovoCure's score of 0.73 indicating that AxoGen is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
AxoGen	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
NovoCure	3 Very Positive mention(s)	0 Positive mention(s)	7 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Is AXGN or NVCR more profitable?

AxoGen has a net margin of -7.91% compared to NovoCure's net margin of -25.93%. AxoGen's return on equity of -14.91% beat NovoCure's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
AxoGen	-7.91%	-14.91%	-7.49%
NovoCure	-25.93%	-41.48%	-12.74%

Do insiders and institutionals hold more shares of AXGN or NVCR?

80.3% of AxoGen shares are owned by institutional investors. Comparatively, 84.6% of NovoCure shares are owned by institutional investors. 7.0% of AxoGen shares are owned by company insiders. Comparatively, 6.3% of NovoCure shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Do analysts prefer AXGN or NVCR?

AxoGen currently has a consensus price target of $16.00, suggesting a potential downside of 15.30%. NovoCure has a consensus price target of $32.67, suggesting a potential upside of 21.75%. Given NovoCure's higher probable upside, analysts plainly believe NovoCure is more favorable than AxoGen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AxoGen	0 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	3.00
NovoCure	0 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.67

Which has stronger valuation & earnings, AXGN or NVCR?

AxoGen has higher earnings, but lower revenue than NovoCure. AxoGen is trading at a lower price-to-earnings ratio than NovoCure, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AxoGen	$159.01M	5.23	-$21.72M	-$0.32	-59.03
NovoCure	$509.34M	5.70	-$207.04M	-$1.40	-19.16

Does the MarketBeat Community prefer AXGN or NVCR?

NovoCure received 24 more outperform votes than AxoGen when rated by MarketBeat users. However, 72.71% of users gave AxoGen an outperform vote while only 63.68% of users gave NovoCure an outperform vote.

Company	Underperform	Outperform
AxoGen	Outperform Votes 453 72.71%	Underperform Votes 170 27.29%
NovoCure	Outperform Votes 477 63.68%	Underperform Votes 272 36.32%

Which has more risk and volatility, AXGN or NVCR?

AxoGen has a beta of 1.01, suggesting that its share price is 1% more volatile than the S&P 500. Comparatively, NovoCure has a beta of 0.64, suggesting that its share price is 36% less volatile than the S&P 500.

Summary

AxoGen beats NovoCure on 10 of the 18 factors compared between the two stocks.